Compile Data Set for Download or QSAR
Report error Found 155 Enz. Inhib. hit(s) with all data for entry = 10930
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492696(Preparation of 1-(4-chloro-3-(trifluoromethyl)phen...)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579120(US11479559, Example 7)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579118(US11479559, Example 5)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492697(Preparation of 1-(4-chloro-3-(trifluoromethyl)phen...)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579127(US11479559, Example 14)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579131(US11479559, Example 18)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579132(US11479559, Example 19)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579130(US11479559, Example 17)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579115(US11479559, Example 2)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492694(US10980809, Example 90 | US11479559, Example 1)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492698(Preparation of 1-(4-chloro-3-(trifluoromethyl)phen...)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579149(US11479559, Example 34 | US11479559, Example 37)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579157(US11479559, Example 42)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579158(US11479559, Example 43)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579155(US11479559, Example 40)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579161(US11479559, Example 46)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579162(US11479559, Example 47)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579159(US11479559, Example 44)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579160(US11479559, Example 45)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579165(US11479559, Example 50)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579166(US11479559, Example 51)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579163(US11479559, Example 48)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579164(US11479559, Example 49)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579135(US11479559, Example 22)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579134(US11479559, Example 21)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579139(US11479559, Example 26)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579140(US11479559, Example 27)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579137(US11479559, Example 24)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579138(US11479559, Example 25)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579145(US11479559, Example 30)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579141(US11479559, Example 28)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579144(US11479559, Example 29)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579149(US11479559, Example 34 | US11479559, Example 37)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579150(US11479559, Example 35)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579186(US11479559, Example 70)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579187(US11479559, Example 71)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579184(US11479559, Example 68)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579185(US11479559, Example 69)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579190(US11479559, Example 74)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579191(US11479559, Example 75)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579188(US11479559, Example 72)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579194(US11479559, Example 78)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579195(US11479559, Example 79)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579192(US11479559, Example 76)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579193(US11479559, Example 77)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579198(US11479559, Example 82)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579196(US11479559, Example 80)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579197(US11479559, Example 81)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579169(US11479559, Example 54)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM579170(US11479559, Example 55)
Affinity DataIC50: 50nMAssay Description:The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:1. Dilution of compounds: a total of 11 c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

Displayed 1 to 50 (of 155 total ) | Next | Last >>
Jump to: